Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema

Journal of Allergy and Clinical Immunology

Volumn 120, Issue 2, 2007, Pages 403-408

  Byrd, James Brian ^a   Shreevatsa, Ajai ^a   Putlur, Pradeep ^a   Foretia, Denis ^a   McAlexander, Laurie ^b   Sinha, Tuhin ^b   Does, Mark D ^c   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Angioedema; angiotensin converting enzyme inhibitor; dipeptidyl peptidase IV; larynx; magnetic resonance imaging; neurokinin; pharmacogenetics; spantide; substance P; trachea

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; SODIUM CHLORIDE; SPANTIDE;

ANGIONEUROTIC EDEMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; EDEMA; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; GENETIC DISORDER; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TRACHEA DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, CD26; BLOOD PRESSURE; CAPTOPRIL; DIPEPTIDYL PEPTIDASES; DISEASE SUSCEPTIBILITY; EDEMA; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, INBRED F344; TRACHEAL DISEASES;

EID: 34547133028     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.04.012     Document Type: Article

References (30)

1. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
3. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 (1993) 1456-1462
4. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
5. Kostis J.B., Kim H.J., Rusnak J., Casale T., Kaplan A., Corren J., et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 165 (2005) 1637-1642
6. Schapira M., Silver L.D., Scott C.F., Schmaier A.H., Prograis Jr. L.J., Curd J.G., et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 308 (1983) 1050-1053
7. Kopp U.C., Farley D.M., and Smith L.A. Bradykinin-mediated activation of renal sensory neurons due to prostaglandin-dependent release of substance P. Am J Physiol 272 suppl (1997) R2009-R2016
8. Campos M.M., and Calixto J.B. Neurokinin mediation of edema and inflammation. Neuropeptides 34 (2000) 314-322
9. Matsas R., Fulcher I.S., Kenny A.J., and Turner A.J. Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli. Proc Natl Acad Sci U S A 80 (1983) 3111-3115
10. Wang L.H., Ahmad S., Benter I.F., Chow A., Mizutani S., and Ward P.E. Differential processing of substance P and neurokinin A by plasma dipeptidyl-(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme. Peptides 12 (1991) 1357-1364
11. Lefebvre J., Murphey L.J., Hartert T.V., Jiao S.R., Simmons W.H., and Brown N.J. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 39 suppl (2002) 460-464
12. Watanabe Y., Kojima T., and Fujimoto Y. Deficiency of membrane-bound dipeptidyl aminopeptidase IV in a certain rat strain. Experientia 43 (1987) 400-401
13. Emanueli C., Grady E.F., Madeddu P., Figini M., Bunnett N.W., Parisi D., et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 31 (1998) 1299-1304
14. Ogasawara T., Kitagawa Y., Ogawa T., Yamada T., Kawamura Y., and Sano K. MR imaging and thermography of facial angioedema: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92 (2001) 473-476
15. Nagatsu T., Hino M., Fuyamada H., Hayakawa T., and Sakakibara S. New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase. Anal Biochem 74 (1976) 466-476
16. Ahmad S., Wang L., and Ward P.E. Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. J Pharmacol Exp Ther 260 (1992) 1257-1261
17. Moreau M.E., Dubreuil P., Molinaro G., Chagnon M., Muller-Esterl W., Lepage Y., et al. Expression of metallopeptidases and kinin receptors in swine oropharyngeal tissues: effects of angiotensin I-converting enzyme inhibition and inflammation. J Pharmacol Exp Ther 315 (2005) 1065-1074
18. Petersson G., Bacci E., McDonald D.M., and Nadel J.A. Neurogenic plasma extravasation in the rat nasal mucosa is potentiated by peptidase inhibitors. J Pharmacol Exp Ther 264 (1993) 509-514
19. Kostis J.B., Packer M., Black H.R., Schmieder R., Henry D., and Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 17 (2004) 103-111
20. Sulpizio A.C., Pullen M.A., Edwards R.M., and Brooks D.P. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat. J Pharmacol Exp Ther 309 (2004) 1141-1147
21. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214 (1993) 829-835
22. Mannucci E., Pala L., Ciani S., Bardini G., Pezzatini A., Sposato I., et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 48 (2005) 1168-1172
23. Marguet D., Baggio L., Kobayashi T., Bernard A.M., Pierres M., Nielsen P.F., et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 97 (2000) 6874-6879
24. Nagakura T., Yasuda N., Yamazaki K., Ikuta H., Yoshikawa S., Asano O., et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 284 (2001) 501-506
25. Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A 100 (2003) 6825-6830
26. Ahren B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.A., et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 (2002) 869-875
27. Ahren B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 2078-2084
28. Herman G.A., Bergman A., Stevens C., Kotey P., Yi B., Zhao P., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91 (2006) 4612-4619
29. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., and Williams-Herman D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006) 2632-2637
30. Grouzmann E., Monod M., Landis B., Wilk S., Brakch N., Nicoucar K., et al. Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J 16 (2002) 1132-1134